[精品课件]分子靶向治疗在淋巴瘤中的应用_14509课件.pptVIP

* * * * Actuarial survival curves for patients with indolent NHL treated at Stanford University from 1960 to 1976, 1976 to 1987, and 1987 to 1996 are essentially indistinguishable, which shows that the widespread use of single-agent or multiagent chemotherapy or combined modality therapy has not had a significant impact on the natural course of the disease.54 * There is now a considerable body of evidence demonstrating a significant clinical benefit with rituximab maintenance therapy in follicular lymphoma (FL). These studies have demonstrated a benefit for rituximab maintenance in previous